Novavax applies for provisional approval of new crown vaccine in New Zealand

Gaithersburg, Maryland, November 4, 2021/PRNewswire/ - Novavax, Inc.

Stanley C.

Novavax has now completed the process of submitting NVX-CoV2373 (recombinant nanoparticle protein new coronary pneumonia vaccine candidate with Matrix-M™ adjuvant) to Medsafe for regulatory review

The submitted information also includes relevant data from the PREVENT-19 trial, a pivotal Phase 3 trial of 30,000 subjects in the United States and Mexico

Novavax recently announced that it has submitted regulatory approvals for its vaccine products in the United Kingdom, Australia and Canada, and has completed all data and modules in the European Union

The company's local partner Biocelect Pty.

About NVX-CoV2373 Phase III Trial

NVX-CoV2373 is being evaluated in two key Phase 3 trials: a trial conducted in the UK showed that the vaccine is 96.

NVX-CoV2373 is a protein-based vaccine candidate, modified from the genetic sequence of the first strain of SARS-CoV-2 (the disease-causing virus of new coronary pneumonia)

Novavax's new crown vaccine is packaged in a ten-dose vial as a ready-to-use liquid formulation

About Matrix-M™ adjuvant

Novavax's patented saponin-based Matrix-M™ adjuvant can stimulate antigen-presenting cells to enter the injection site, enhance the antigen presentation of local lymph nodes, and thereby enhance the immune response.

About Novavax

Novavax, Inc.

For more information, please visitor contact us via Twitter and LinkedIn

Forward-looking statements

The statements in this article regarding the following are forward-looking statements: Novavax's future situation, operating plans and prospects, partnerships, continuous development of NVX-CoV2373 and other Novavax vaccine candidates, the scope, timing and results of future regulatory filings